B
KZR

Bailard’s Kezar Life Sciences KZR Stock Holding History

Bailard’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,902
Closed -$164K – 754
2022
Q3 		$164K Buy
+1,902
New +$185K 0.01% 618

Other funds holding KZR

APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Bailard's KZR Position: Q4 2022 in Review

Bailard sold out of Kezar Life Sciences (KZR) in Q4 2022, closing a stake of 1,902 shares — an estimated $164K sold.

Bailard first reported a position in KZR in Q3 2022 and held it in 1 quarter. The position peaked at $164K in Q3 2022. 123 funds tracked by Wall St. Rank hold KZR as of Q4 2022.

  • Bailard reported no remaining Kezar Life Sciences position as of Q4 2022 after selling out during the quarter.
  • Bailard sold 1,902 Kezar Life Sciences shares in Q4 2022, an estimated $164K.
  • Bailard first reported a position in Kezar Life Sciences in Q3 2022 and held it in 1 quarter.
  • Bailard's Kezar Life Sciences position peaked at $164K in Q3 2022.
  • 123 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q4 2022.

Based on Bailard's 13F filing for Q4 2022, filed 2 Feb 2023.